Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PHAR Catalyst Timeline
Dated clinical, regulatory and corporate events for Pharming Group N.V.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pharming Group N.V.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How PHAR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-14 | leniolisib | Phase 2 topline data readout | Phase 2 |
Drug Pipeline Intelligence
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| RUCONEST | |||
| JOENJA |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Leniolisib Small MoleculesMarketedNCT05438407 | APDS | Approved | ACTIVE NOT_RECRUITING | 31 | Dec 30, 2026 | ||||||
| Leniolisib Small MoleculesNCT06990529 | PIDs Linked to PI3K | Phase 2 | ACTIVE NOT_RECRUITING | 12 | Aug 12, 2029 | ||||||
| Napazimone Small MoleculesNCT05650229 | Primary Mitochondrial Disease | Phase 2 | RECRUITING | 180 | Nov 1, 2027 | ||||||
| Napazimone Small MoleculesNCT03888716 | Mitochondrial Disease | Phase 2 | COMPLETED | 226 | Mar 16, 2021 | ||||||
| Leniolisib Small MoleculesNot countedNCT06549114 | Primary Immunodeficiency Disorders (PIDs) | Phase 2 | COMPLETED | 13 | Jun 23, 2026 | ||||||
| Leniolisib Small MoleculesNot countedNCT06897358 | Common Variable Immunodeficiency (CVID) | Phase 2 | COMPLETED | 27 | Aug 12, 2026 | ||||||
| Recombinant human C1 inhibitor BiologicsNot countedNCT02247739 | Hereditary Angioedema | Phase 3 | COMPLETED | 184 | Sep 1, 2016 | ||||||
| Recombinant human C1 inhibitor Small MoleculesNot countedNCT00851409 | Genetic Disorders | Phase 2 | COMPLETED | 25 | Apr 1, 2010 | ||||||
| Ruconest Small MoleculesNot countedNCT04530136 | Confirmed Coronavirus Disease | Phase 2 | COMPLETED | 38 | Dec 1, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every PHAR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| leniolisib PriorityOrphan | genetic primary immunodeficiencies (PIDs) with immune dysregulation | Phase 2 | 2026-10-14 | spleen volume reduction: 26.4% (n=11); lymph node reduction: 33.7% (n=4); pulmonary function improvement: 8.0% (n=7)Read More | Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in PHAR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PHAR for Q3 2026. | ||||
Ownership Trends
PHAR Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How PHAR ranks across every disease it competes in
PHAR News
Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London
Pharming announced its participation in the 2026 Jefferies Global Healthcare Conference in London, scheduled for November 16-19, 2026. Key executives, including Interim Co-CEOs and the VP of Investor Relations, will host a fireside chat on November 18. A live webcast will be available for those unable to attend in person.
Read more →MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.
The U.K. MHRA has approved Pharming's Joenja (leniolisib) for children aged 4 to 11 with activated PI3K delta syndrome (APDS). This marks the first treatment specifically for this age group in the U.K. Joenja is expected to be available by February 2027, expanding access for younger patients suffering from this rare immunodeficiency.
Read more →Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November
Pharming Group reported a 21% increase in total revenues for Q3 2026, reaching $117.6 million, driven by strong demand for RUCONEST and Joenja. Operating profit rose 89% to $29.9 million, and the company tightened its revenue guidance for the year. Positive Phase II data for leniolisib in genetic PIDs was also announced, with further data expected in November.
Read more →Pharming Group announces third quarter 2026 revenues above market expectations
Pharming Group reported third quarter 2026 revenues of approximately US$117.6 million, a 21% increase from the same period in 2025. The company tightened its full-year revenue guidance to between US$380 million and US$390 million. Key revenue drivers included strong performances from RUCONEST and Joenja, with significant growth in international demand.
Read more →Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026
Pharming presented positive topline data from its Phase II trial of leniolisib for genetic primary immunodeficiencies (PIDs) with immune dysregulation. The trial demonstrated that leniolisib was well-tolerated and resulted in significant improvements in spleen volume, lymph node size, and pulmonary function. All participants who completed the trial chose to continue in a long-term extension study, indicating strong interest in the treatment's potential.
Read more →Pharming announces CEO transition
Pharming has announced a leadership transition as CEO Fabrice Chouraqui steps down. The Board of Directors appointed Leverne Marsh and Kenneth Lynard as Interim Co-CEOs to ensure continuity. The decision follows a mutual agreement on differing views regarding the company's strategic direction. Pharming's commitment to its patients and strategic priorities remains intact.
Read more →Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS
Pharming announced that the FDA has accepted its supplemental New Drug Application for lower doses of Joenja, aimed at treating children aged 4 years and older with activated phosphoinositide 3-kinase delta syndrome (APDS). The application has been granted Priority Review, with a target action date set for January 30, 2027. This follows the recent approval of Joenja for older children weighing at least 27 kg, expanding access to younger patients.
Read more →Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
Pharming announced positive topline data from its Phase II trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation. The results, accepted as a late-breaking abstract for ESID 2026, highlighted significant clinical improvements, including a mean 26.4% reduction in spleen volume. The drug was well-tolerated, with no new safety signals reported. Pharming plans to present additional data at the conference and expects to report results for leniolisib in common variable immunodeficiency (CVID) later this year.
Read more →FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.
Pharming's Joenja (leniolisib) has received FDA approval for use in children aged 4 to 11 with activated phosphoinositide 3-kinase delta syndrome (APDS). This marks the first FDA-approved treatment for this age group in the U.S. The new dosing options will be available in October, providing a critical intervention for managing APDS symptoms and improving children's health outcomes.
Read more →Pharming Group to participate in September investor conferences
Pharming Group N.V. announced its participation in two investor conferences in September 2026. CEO Fabrice Chouraqui will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, followed by participation in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15. The company encourages scheduling one-on-one meetings with its management team.
Read more →Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
Pharming Group has launched Joenja (leniolisib) in Japan for patients aged 4 and older with activated PI3K delta syndrome (APDS). This marks the first commercial availability of Joenja for children aged 4 to 11 globally. The launch follows its approval by Japan's Ministry of Health and highlights Pharming's commitment to rare disease treatment.
Read more →Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
Pharming Group N.V. will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12-13, 2026. Michael Levitan, VP of Investor Relations, will lead a Fireside Chat Q&A session on August 12. The company invites interested parties to schedule meetings with its management team during the conference.
Read more →Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
Pharming Group N.V. reported a 3% decrease in total revenues for Q2 2026, totaling $90.2 million. While RUCONEST revenue fell by 10%, Joenja saw a significant 40% increase. The company revised its revenue guidance downward but remains optimistic about the growth potential of Joenja and upcoming clinical data readouts. Pharming is also focusing on operational efficiency and expanding its rare disease portfolio.
Read more →Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30
Pharming Group N.V. will report its preliminary financial results for the second quarter and first half of 2026 on July 30, 2026. The company will also provide a business update during a conference call and webcast scheduled for the same day. Interested participants must register in advance to access the call.
Read more →Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
Pharming Group announced the FDA's acceptance of its resubmitted supplemental New Drug Application for Joenja (leniolisib) to treat children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). If approved, Joenja will be the first treatment for this rare immunodeficiency in the U.S. The resubmission includes additional data requested by the FDA and has a target action date of October 24, 2026.
Read more →Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York
Pharming Group announced its participation in the 2026 Jefferies Global Healthcare Conference in New York, scheduled for June 3-4, 2026. CEO Fabrice Chouraqui will take part in a Fireside Chat Q&A session on June 4 at 11:05am EDT. The event will be accessible via a live webcast and replay on Pharming's website.
Read more →Pharming Group announces results of 2026 Annual General Meeting of Shareholders
Pharming Group held its Annual General Meeting of Shareholders on May 28, 2026, where all proposed agenda items were approved. Key decisions included the appointment of KPMG as the independent auditor for 2026-2028 and amendments to the remuneration policy for Non-Executive Directors. Shareholders also renewed authorizations for share issuance and repurchase.
Read more →European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union
The European Commission has granted marketing authorization for Joenja® (leniolisib), marking it as the first approved treatment for activated PI3K delta syndrome (APDS) in the EU. The drug is expected to launch in Germany in Q3 2026. This approval follows previous approvals in several countries, reinforcing Pharming's commitment to addressing rare diseases.
Read more →Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders
Pharming Group N.V. announced its participation in the 2026 Annual Meeting of the Clinical Immunology Society, where it will present interim outcomes from a long-term study of leniolisib in pediatric patients with activated PI3Kδ syndrome (APDS). The presentations will also cover clinical data from leniolisib's use in treating immune dysregulation in patients with Common Variable Immunodeficiency (CVID) and related disorders. Two phase II trials are currently evaluating leniolisib's safety and tolerability in these patient populations.
Read more →Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026
Pharming Group reported its Q1 2026 financial results, revealing total revenues of $72.4 million, an 8% decrease from the previous year. Notably, Joenja® saw a 34% revenue increase, driven by strong uptake in the U.S. and international markets. The company reaffirmed its revenue guidance for 2026 and made significant regulatory progress, including approvals in Japan and a positive opinion from the CHMP in Europe.
Read more →